The final approved version will be numbered as Version 1.0. Revisions after the “Final” version will be numbered as Version 1.x. The Clinical Study Report will document any changes made after the final version approved before database lock. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 27 of 63 7. DEMOGRAPHIC , OTHER BASELINE CHARACTERISTICS AND MEDICATION 7.1. PATIENT DISPOSITION AND WITHDRAWALS The number of patients who were screened, treated and completed initial treatment with SL-701, will be tabulated. Patients will be considered to have completed the initial treatment if they received either 12 injections (Stage 1) or 16 injections (Stage 2) of SL-701. The reasons for discontinuing study drug will also be tabulated. The first and last dates of administration of study drug, the date of treatment completion or discontinuation, and the reason for discontinuation of study drug will be listed. For scree n failures, the listing will report the reasons that patients failed screening. A listing will identify the analysis populations to which each patient belong ed. The patient disposition, withdrawal, and analysis population tables and listings will be reported using all enrolled patients. 7.2. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS Demographic (ie, gender, age, race and ethnicity) and baseline characteristics (ie, height, weight, body mass index (BMI) and score on the Karnofsky Performance Status scale (Appendix 3) will be summarized using descriptive statistics and the Treated Population. Age will be calculated as the p atient’s age at the time of signing ICF as follows: Age = (time of signing ICF ) - date of birth + 1) / 365.25 and truncated to complete years. BMI (kg/m2) = Weight(kg)/[Height(m)2] Demographic data and available baseline characteristics will be listed for all patients i n the ITT Population. 7.3.